NuVasive to Participate in 42nd Annual Cowen Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Credit Suisse Positive on NuVasive (NUVA), 'Momentum Improving, Driven by Critical Mass of New Products and Growth Drivers', Street High PT $75
February 24, 2022 2:15 PM ESTCredit Suisse analyst Matt Miksic lowered the price target on NuVasive (NASDAQ: NUVA) to $75.00 (from $83.00) while maintaining a Outperform rating.
The analyst comments "Spine Momentum Results in a Better-Than-Expected Finish, Despite COVID and Staffing Challenges: Mgmts strategy combining new and innovative product launches and enabling technology showed solid results in terms of... More
